A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: A one-year mirror-image study with national claim-based database in Taiwan

Journal of Psychiatric Research

Volumn 46, Issue 6, 2012, Pages 751-756

  Chang, Hui Chih ^a,b   Tang, Chao Hsiun ^a   Huang, Sheng Tzu ^a   McCrone, Paul ^b   Su, Kuan Pin ^b,c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Mirror image study; Psychiatric Inpatients Medical Claims Data (PIMC); Relapse; Service costs

Indexed keywords

CLOZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; OUTPATIENT CARE; PRIORITY JOURNAL; SCHIZOPHRENIA; TAIWAN;

EID: 84862800854     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.02.019     Document Type: Article

References (25)

1. Altamura A.C., Bobo W.V., Meltzer H.Y. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology 2007, 22:249-267.
2. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2.
3. Chang H.C., Tang C.H., Tsai S.J., Yen F.C., Su K.P. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. Journal of Clinical Psychiatry 2009, 70:141.
4. Davies L.M., Drummond M.F. Economics and schizophrenia: the real cost. British Journal of Psychiatry 1994, (Suppl.):18-21.
5. Kane J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry 2003, 64(Suppl. 16):34-40.
6. Keith S.J., Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal of Clinical Psychiatry 2003, 64:1308-1315.
7. Knapp M., King D., Pugner K., Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. British Journal of Psychiatry 2004, 184:509-516.
8. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002, 63:892-909.
9. Lambert T., Olivares J.M., Peuskens J., Desouza C., Kozma C.M., Otten P., et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Annals of General Psychiatry 2011, 10(10).
10. Leal A., Rosillon D., Mehnert A., Jarema M., Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and Drug Safety 2004, 13:811-816.
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005, 353:1209-1223.
12. Mauskopf J.A., Paul J.E., Grant D.M., Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998, 13:277-288.
13. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
14. Mullins C.D., Obeidat N.A., Cuffel B.J., Naradzay J., Loebel A.D. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research 2008, 98:8-15.
15. Niaz O.S., Haddad P.M. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatrica Scandinavica 2007, 116:36-46.
16. Olivares J.M., Peuskens J., Pecenak J., Resseler S., Jacobs A., Akhras K.S. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Current Medical Research and Opinion 2009, 25:2197-2206.
17. Olivares J.M., Rodriguez-Martinez A., Buron J.A., onso-Escolano D., Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Applied Health Economics and Health Policy 2008, 6:41-53.
18. Peuskens J., Olivares J.M., Pecenak J., Tuma I., Bij de W.H., Eriksson L., et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Current Medical Research and Opinion 2010, 26:501-509.
19. Rice D.P. The economic impact of schizophrenia. Journal of Clinical Psychiatry 1999, 60(Suppl. 1):4-6.
20. Shepherd M., Watt D., Falloon I., Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine Monograph Supplement 1989, 15:1-46.
21. Su K.P., Chang H.C., Tsai S.J., Yen F.C., Tang C.H. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value in Health 2009, 12(Suppl. 3):S118-S121.
22. Taylor D.M., McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 2000, 101:416-432.
23. van O.J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
24. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophrenia Bulletin 1995, 21:419-429.
25. Young C.L., Taylor D.M. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatrica Scandinavica 2006, 114:14-20.